{
    "clinical_study": {
        "@rank": "132964", 
        "arm_group": [
            {
                "arm_group_label": "DCVAC/OvCa in parallel with chemo (SoC)", 
                "arm_group_type": "Experimental", 
                "description": "Combination therapy with DCVAC/OvCa and Standard of Care (SoC)"
            }, 
            {
                "arm_group_label": "Standard of Care (Chemotherapy)", 
                "arm_group_type": "Active Comparator", 
                "description": "Standard of Care as an Active Comparator (Paclitaxel or topotecan or doxorubicin is Standard of Care First Line Chemotherapy)"
            }
        ], 
        "brief_summary": {
            "textblock": "The purpose of this study is to determine whether DCVAC/OvCa added to Standard of Care\n      chemotherapy may result in prolongation of Overall Survival (OS)."
        }, 
        "brief_title": "Efficacy of DCVAC/OvCa Plus Standard of Care in Relapsed Platinum Resistant Epithelial Ovarian Carcinoma", 
        "completion_date": {
            "#text": "June 2016", 
            "@type": "Anticipated"
        }, 
        "condition": "Epithelial Ovarian Carcinoma", 
        "condition_browse": {
            "mesh_term": [
                "Carcinoma", 
                "Ovarian Neoplasms", 
                "Neoplasms, Glandular and Epithelial"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Females 18 years or older\n\n          -  Histologically confirmed International Federation of Gynecology and Obstetrics (FIGO)\n             Stage III epithelial ovarian, primary peritoneal, or fallopian tube carcinoma\n             (serous, endometrioid or mucinous), who have undergone initial surgery or interval\n             debulking surgery but have not reached complete remission of more than 6 months after\n             first line platinum based chemotherapy, for one of the following reasons\n\n          -  Patients are platinum-refractory (no response)\n\n          -  Complete remission was not reached (partial responders)\n\n          -  Relapse within \u22646 months of remission (Platinum-resistant)\n\n          -  Platinum-based chemotherapy failure should have been confirmed by computerized\n             tomography (CT)/magnetic resonance imaging (MRI) scan (Platinum-resistant) or by\n             finding described as 'did not reach complete clinical remission' (Platinum-refractory\n             or Platinum-partial response) Patients must have at least one measureable target\n             lesion as defined by the Response Evaluation Criteria In Solid Tumors (RECIST) 1.1\n             criteria\n\n          -  Eastern Cooperative Oncology Group (ECOG) Performance status 0\u22122\n\n        Exclusion Criteria:\n\n          -  FIGO I,II,IV epithelial ovarian cancer\n\n          -  FIGO III clear cells epithelial ovarian cancer\n\n          -  Non-epithelial ovarian cancer\n\n          -  Borderline tumors (tumors of low malignant potential)\n\n          -  Prior or current systemic anti-cancer therapy for ovarian cancer [for example\n             chemotherapy, monoclonal antibody therapy, tyrosine kinase inhibitor therapy,\n             vascular endothelial growth factor (VEGF) therapy or hormonal therapy] except first\n             line Platinum-based chemotherapy (with or without bevacizumab)\n\n          -  Previous radiotherapy to the abdomen and pelvis\n\n          -  Malignancy other than epithelial ovarian cancer, except those that have been in\n             clinical remission (CR) for a minimum of 3 years, and except carcinoma in-situ of the\n             cervix or non-melanoma skin carcinomas\n\n          -  Clinically significant cardiovascular disease\n\n          -  Active autoimmune disease requiring treatment\n\n          -  History of severe forms of primary immune deficiencies\n\n          -  Systemic immunosuppressive therapy for any reason"
            }, 
            "gender": "Female", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "60", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "April 4, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02107378", 
            "org_study_id": "SOV03"
        }, 
        "intervention": [
            {
                "arm_group_label": "DCVAC/OvCa in parallel with chemo (SoC)", 
                "description": "DCVAC/OvCa is the experimental therapy added on to Paclitaxel or topotecan or doxorubicin", 
                "intervention_name": "DCVAC/OvCa", 
                "intervention_type": "Biological"
            }, 
            {
                "arm_group_label": "Standard of Care (Chemotherapy)", 
                "description": "Paclitaxel or topotecan or doxorubicin is Standard of Care First Line Chemotherapy", 
                "intervention_name": "Standard of Care (Paclitaxel or topotecan or doxorubicin)", 
                "intervention_type": "Drug", 
                "other_name": [
                    "Paclitaxel", 
                    "topotecan", 
                    "doxorubicin"
                ]
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Doxorubicin", 
                "Paclitaxel", 
                "Topotecan"
            ]
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "Immunotherapy", 
            "Serous", 
            "Relapsed", 
            "Platinum resistant (pt)", 
            "Ovarian Cancer (OvCa)", 
            "Biological", 
            "Vaccine"
        ], 
        "lastchanged_date": "April 7, 2014", 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Brno", 
                        "country": "Czech Republic", 
                        "zip": "625 00"
                    }
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Ceske Budejovice", 
                        "country": "Czech Republic", 
                        "zip": "370 01"
                    }
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Hradec Kr\u00e1lov\u00e9", 
                        "country": "Czech Republic", 
                        "zip": "500 05"
                    }
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Liberec", 
                        "country": "Czech Republic", 
                        "zip": "460 63"
                    }
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Olomouc", 
                        "country": "Czech Republic", 
                        "zip": "775 20"
                    }
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Ostrava", 
                        "country": "Czech Republic", 
                        "zip": "708 52"
                    }
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Prague", 
                        "country": "Czech Republic", 
                        "zip": "150 06"
                    }
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Cologne", 
                        "country": "Germany", 
                        "zip": "50931"
                    }
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Dresden", 
                        "country": "Germany", 
                        "zip": "01307"
                    }
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Erlangen", 
                        "country": "Germany", 
                        "zip": "91054"
                    }
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Leipzig", 
                        "country": "Germany", 
                        "zip": "04103"
                    }
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Bialystok", 
                        "country": "Poland", 
                        "zip": "15-276"
                    }
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Gliwice", 
                        "country": "Poland", 
                        "zip": "45-101"
                    }
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Krakow", 
                        "country": "Poland", 
                        "zip": "31-501"
                    }
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Lublin", 
                        "country": "Poland", 
                        "zip": "20-081"
                    }
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Poznan", 
                        "country": "Poland", 
                        "zip": "60-569"
                    }
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Rybnik", 
                        "country": "Poland", 
                        "zip": "44-200"
                    }
                }, 
                "status": "Recruiting"
            }
        ], 
        "location_countries": {
            "country": [
                "Czech Republic", 
                "Germany", 
                "Poland"
            ]
        }, 
        "number_of_arms": "2", 
        "official_title": "A Randomized, Open-label, Parallel Group, Multi-center Phase II Clinical Trial Evaluating Effect of Addition of DCVAC/OvCa to Standard Chemotherapy in Women With Relapsed Platinum (Pt)-Resistant Epithelial Ovarian Carcinoma", 
        "overall_contact": {
            "email": "kapsa@sotio.com", 
            "last_name": "Richard Kapsa", 
            "phone": "(+420) 2241 74448)"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": [
                "European Union: European Medicines Agency", 
                "Czech Republic: State Institute for Drug Control", 
                "Poland: Office for Registration of Medicinal Products, Medical Devices and Biocidal Products", 
                "Germany: Paul-Ehrlich-Institut"
            ], 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "April 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "Overall survival (all cause mortality)", 
            "safety_issue": "Yes", 
            "time_frame": "72 weeks"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02107378"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "Per modified RECIST", 
                "measure": "Progression Free Survival", 
                "safety_issue": "No", 
                "time_frame": "72 weeks"
            }, 
            {
                "description": "Per RECIST", 
                "measure": "Objective Response Rate", 
                "safety_issue": "No", 
                "time_frame": "0, 8, 16, ,24, 32, 40, 48, 56, 64, 72 weeks"
            }, 
            {
                "measure": "Biological Progression Free Interval", 
                "safety_issue": "No", 
                "time_frame": "0, 8, 16, 24, 32, 40, 48, 56, 64, 72 weeks"
            }, 
            {
                "measure": "Immunological Response", 
                "safety_issue": "No", 
                "time_frame": "0, 4, 8, 12, 16, 20, 24, 28, 32, 36, 40 weeks"
            }, 
            {
                "measure": "Frequency of Adverse Events", 
                "safety_issue": "Yes", 
                "time_frame": "0, 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 48, 56, 64, 72 weeks"
            }, 
            {
                "measure": "Evaluation of Quality of Life via Functional Assessment of Cancer Therapy-Ovarian", 
                "safety_issue": "No", 
                "time_frame": "0, 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 48, 56, 64, 72 weeks"
            }
        ], 
        "source": "Sotio a.s.", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Sotio a.s.", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "January 2014", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "April 2014"
    }
}